Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection

AIDS

Volumn 17, Issue 14, 2003, Pages 2015-2023

  Lange, Christoph G ^a   Lederman, Michael M ^a,c   Medvik, Kathy ^a   Asaad, Robert ^a   Wild, Mary ^b   Kalayjian, Robert ^b   Valdez, Hernan ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

CD28; CD4 nadir; HAART; Immune reconstitution; Immune response score; Immunization; Lymphocyte proliferative responses

Indexed keywords

ANTIBODY; ANTIGEN; ANTIRETROVIRUS AGENT; CD28 ANTIGEN; CD4 ANTIGEN; DIPHTHERIA VACCINE; KEYHOLE LIMPET HEMOCYANIN; TETANUS TOXOID; VIRUS RNA;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CALCULATION; CELL COUNT; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG RESPONSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOCOMPETENCE; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MODEL; MOLECULE; OUTPATIENT DEPARTMENT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SERODIAGNOSIS; T LYMPHOCYTE; UNITED STATES;

ADULT; AGED; ANTIBODY FORMATION; ANTIGENS, CD28; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; PHENOTYPE; PROSPECTIVE STUDIES; T-LYMPHOCYTES;

EID: 0142030023     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200309260-00002     Document Type: Article

References (52)

1. Miedema F, Petit AJ, Terpstra FG, Schattenkerk JK, de Wolf F, Al BJ, et al. Immunological abnormalities in human immunodeficiency virus (HIV)- infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. J Clin Invest 1988, 82:1908-1914.
2. Lane HC, Depper JM, Greene WC, Whalen G, Waldmann TA, Fauci AS. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med 1985, 313:79-84.
3. Lang W, Perkins H, Anderson RE, Royce R, Jewell N, Winkelstein W, Jr. Patterns of T lymphocyte changes with human immunodeficiency virus infection: from seroconversion to the development of AIDS. J Acquir Immune Defic Syndr 1989, 2:63-69.
4. Dolan MJ, Clerici M, Blatt SP, Hendrix CW, Melcher GP, Boswell RN, et al. In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis 1995, 172:79-87.
5. Clerici M, Stocks NI, Zajac RA, Boswell RN, Lucey DR, Via CS, et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. J Clin Invest 1989, 84:1892-1899.
6. Palella FJ, Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
7. Valdez H, Chowdhry TK, Asaad R, Woolley IJ, Davis T, Davidson R, et al. Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995-1999. Clin Infect Dis 2001, 32:1487-1493.
8. Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000, 356:291-296.
9. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller A, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998, 352:1725-1730.
10. Valdez H, Connick E, Smith KY, Lederman MM, Bosch RJ, Kim RS, et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002, 16:1859-1866.
11. Tortajada C, Garcia F, Plana M, et al. Comparison of T-cell Subsets' reconstitution after 12 months of highly active antiretroviral therapy initiated during early versus advanced states of HIV disease. J Acquir Immune Defic Syndr 2000, 25: 296-305.
12. Powderly WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy: the end of opportunism? JAMA 1998, 280:72-77.
13. Martin M, Echevarria S, Leyva-Cobian F, Pereda I, Lopez-Hoyos M. Limited immune reconstitution at intermediate stages of HIV-1 infection during one year of highly active antiretroviral therapy in antiretroviral-naive versus non-naive adults. Eur J Clin Microbiol Infect Dis 2001, 20:871-879.
14. Mezzaroma I, Carlesimo M, Pinter E, Alario C, Sacco G, Muratori DS, et al. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease. AIDS 1999, 13:1187-1193.
15. Lange CG, Valdez H, Medvik K, Asaad R, Lederman MM. CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin Immunol 2002, 102:154-161.
16. Lederman MM, McKinnis R, Kelleher D, Cutrell A, Mellors J, Neisler M, et al. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS 2000, 14:2635-2642.
17. Lederman MM. Immune restoration and CD4+ T-cell function with antiretroviral therapies. AIDS 2001, 15(Suppl 2):S11-s15.
18. Kaufmann GR, Zaunders J, Cooper DA. Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy. Sex Transm Infect 1999, 75:218-224.
19. Cozzi-Lepri AC, Phillips AN, d'Arminio Monforte A, Castelli F, Antinori A, et al. When to start highly active antiretroviral therapy in chronically HIV-1infected patients: evidence from the ICONA study. AIDS 2001, 15:983-990.
20. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001, 286:2568-2577.
21. Opravil M, Ledergerber B, Furrer H, Hirschel B, Imhof A, Gallant S, et al. Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count above 350/μl. AIDS 2002, 16:1371-1381.
22. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 2001, 15:2251-2257.
23. Valdez H, Smith KY, Landay A, Connick E, Kuritzkes DR, Kessler H, et al. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS 2000, 14:11-21.
24. Valdez H, Mitsuyasu R, Landay A, Sevin AD, Chan ES, Spritzler J, et al. Interleukin-2 increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5O46s. J Infect Dis 2003, 187:320-325.
25. Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St Clair M, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998, 178:70-79.
26. Sokal JE. Editorial: Measurement of delayed skin-test responses. N Engl J Med 1975, 293:501-502.
27. Birx DL, Rhoads JL, Wright JC, Burke DS, Redfield RR. Immunologic parameters in early-stage HIV-seropositive subjects associated with vaccine responsiveness. J Acquir Immune Defic Syndr 1991, 4:188-196.
28. Kroon FP, van Dissel JT, Labadie J, van Loon AM, van Furth R. Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus. Clin Infect Dis 1995, 21:1197-1203.
29. Kurtzhals JA, Kjeldsen K, Heron I, Skinhoj P. Immunity against diphtheria and tetanus in human immunodeficiency virus-infected Danish men born 1950-59. APMIS 1992, 100:803-808.
30. Connick E, Lederman MM, Kotzin BL, Spritzler J, Kuritzkes DR, St. Clair M, et al. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis 2000, 181:358-363.
31. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998, 351:1682-1686.
32. Rizzardi GP, Tambussi G, Bart PA, Chapuis AG, Lazzarin A, Pantaleo G. Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count. AIDS 2000, 14:2257-2263.
33. Phillips AN, Sabin CA, Elford J, Bofill M, Janossy G, Lee CA. Use of CD4 lymphocyte count to predict long-term survival free of AIDS after HIV infection. BMJ 1994, 309:309-313.
34. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002, 360:119-129.
35. Kroon FP, Rimmelzwaan GF, Roos MT, Osterhaus AD, Hamann D, Miedema F, et al. Restored humoral immune response to influenza vaccination in HIV- infected adults treated with highly active antiretroviral therapy. AIDS 1998, 12:F217-F223.
36. Fowke KR, D'Amico R, Chernoff DN, Pottage JC, Jr., Benson CA, Sha BE, et al. Immunologic and virologic evaluation after influenza vaccination of HIV- 1-infected patients. AIDS 1997, 11:1013-1021.
37. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
38. Connick E. Immune reconstitution in HIV-1-infected individuals treated with potent antiretroviral therapy. J Invest Dermatol Symp Proc 2001, 6:212-218.
39. Connors M, Kovacs JA, Krevat S, Gea-Banacloche JC, Sneller MC, Flanigan M, et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Med 1997, 3:533-540.
40. Knapp S, Lenz P, Gerlitz S, Rieger A, Meier S, Stingl G. Highly active antiretroviral therapy responders exhibit a phenotypic lymphocyte pattern comparable to that of long-term nonprogressors. Int Arch Allergy Immunol 2001, 126:248-256.
41. Pakker NG, Roos MT, van Leeuwen R, de Jong MD, Koot M, Reiss P, et al. Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16:318-326.
42. Pakker NG, Notermans DW, de Boer RJ, Roos MT, de Wolf F, Hill A, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nature Med 1998, 4:208-214.
43. Kammerer R, Iten A, Frei PC, Burgisser P. Expansion of T cells negative for CD28 expression in HIV infection. Relation to activation markers and cell adhesion molecules, and correlation with prognostic markers. Med Microbiol Immunol (Berl) 1996, 185:19-25.
44. Brinchmann JE, Dobloug JH, Heger BH, Haaheim LL, Sannes M, Egeland T. Expression of costimulatory molecule CD28 on T cells in human immunodeficiency virus type 1 infection: functional and clinical correlations. J Infect Dis 1994, 169: 730-738.
45. Haffar OK, Smithgall MD, Wong JG, Bradshaw J, Linsley PS. Human immunodeficiency virus type 1 infection of CD4+ T cells down- regulates the expression of CD28: effect on T cell activation and cytokine production. Clin Immunol Immunopathol 1995, 77:262-270.
46. Allison JP. CD28-B7 interactions in T-cell activation. Curr Opin Immunol 1994, 6:414-419.
47. Sieg SF, Mitchem JB, Bazdar DA, Lederman MM. Close link between CD4+ and CD8+ T cell proliferation defects in patients with human immunodeficiency virus disease and relationship to extended periods of CD4+ lymphopenia. J Infect Dis 2002, 185:1401-1416.
48. Sieg SF, Harding CV, Lederman MM. HIV-1 infection impairs cell cycle progression of CD4(+) T cells without affecting early activation responses. J Clin Invest 2001, 108:757-764.
49. Lange C, Lederman, M, Sierra Madero J, Medvik K, Asaad R, et al. Impact of suppression of viral replication by highly active antiretroviral therapy (HAART) on immune function and phenotype in chronic HIV-1 infection. J Acquir Immunodef Syndr 2002, 30:33-40.
50. Roos MT, Miedema F, Meinesz AP, De Leeuw NA, Pakker NG, Lange JM, et al. Low T cell reactivity to combined CD3 plus CD28 stimulation is predictive for progression to AIDS: correlation with decreased CD28 expression. Clin Exp Immunol 1996, 105:409-415.
51. Gea-Banacloche JC, Clifford Lane H. Immune reconstitution in HIV infection. AIDS 1999, 13:S25-38.
52. Tilling R, Kinloch S, Goh LE, Cooper D, Perrin L, Lampe F, et al. Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. AIDS 2002, 16:589-596.